Damian Garde

Damian Garde is a reporter at Bloomberg, covering the pharmaceutical industry and healthcare policy. He previously worked at Reuters and Financial Times. His articles focus on drug approvals, mergers and acquisitions in the biotech sector, and government negotiations with pharmaceutical companies over drug prices. Garde has reported on Merck's pneumonia vaccine approval, Pfizer's gene therapy failure, Lilly's Alzheimer's drug effectiveness, and Bristol-Myers Squibb's financial performance. His work often highlights conflicts of interest within the pharmaceutical industry and the impact of government regulation on drug prices.

Biography:  https://www.bloomberg.com/authors/AWztgiD8PJg/damian-garde

100%

The overall score is a weighted number that takes into account conflict of interest, bias, deception and other practices that undermines the credibility of the source. It is calculated as:
Analysis.OverallConflictOfInterestScore * 0.3F + Analysis.OverallBiasScore * 0.3F + Analysis.DeceptivenessScore * 0.3F + Analysis.ReadabilityScore * 0.1F

A score that takes into consideration the content for flow, interruptions with ads, and overt search engine optimization techniques that makes the content hard to understand

The Daily's Verdict

This author is known for its high journalistic standards. The author strives to maintain neutrality and transparency in its reporting, and avoids conflicts of interest. The author has a reputation for accuracy and rarely gets contradicted on major discrepancies in its reporting.

Bias

100%

Examples:

No current examples available.

Conflicts of Interest

100%

Examples:

No current examples available.

Contradictions

100%

Examples:

No current examples available.

Deceptions

100%

Examples:

No current examples available.

Recent Articles

New Merck Vaccine, Capvaxive, Secures FDA Approval for Adult Protection Against Pneumococcal Diseases: 85% Effectiveness and Fewer Side Effects Than Pfizer's Prevnar

New Merck Vaccine, Capvaxive, Secures FDA Approval for Adult Protection Against Pneumococcal Diseases: 85% Effectiveness and Fewer Side Effects Than Pfizer's Prevnar

Broke On: Monday, 17 June 2024 Merck's new pneumococcal vaccine, Capvaxive, receives FDA approval for protecting adults from bacterial infections leading to pneumonia and meningitis. With coverage against 21 strains of bacteria and ability to prevent 85% of invasive diseases in older adults, it aims to surpass Pfizer's Prevnar. Capvaxive is well-tolerated with common side effects including pain, fatigue, headache, and muscle aches. No reports of Guillain-Barré syndrome have been recorded.